Show simple item record

Files in this item

Item metadata

dc.contributor.authorMocniak, Katarzyna Anna
dc.contributor.authorKubajewska, Ilona
dc.contributor.authorSpillane, Dominic E.M.
dc.contributor.authorWilliams, Gareth R.
dc.contributor.authorMorris, Russell Edward
dc.date.accessioned2015-11-06T16:40:05Z
dc.date.available2015-11-06T16:40:05Z
dc.date.issued2015
dc.identifier.citationMocniak , K A , Kubajewska , I , Spillane , D E M , Williams , G R & Morris , R E 2015 , ' Incorporation of cisplatin into the metal-organic frameworks UiO66-NH 2 and UiO66 – encapsulation vs. conjugation. ' RSC Advances , vol. 5 , no. 102 , pp. 83648-83656 . DOI: 10.1039/C5RA14011Ken
dc.identifier.issn2046-2069
dc.identifier.otherPURE: 221674653
dc.identifier.otherPURE UUID: b3b53f47-bb29-44c3-805d-80644897f250
dc.identifier.otherScopus: 84944096789
dc.identifier.urihttp://hdl.handle.net/10023/7753
dc.descriptionThe authors wish to thank the EPSRC (EP/K005499/1 and EP/K025112/1) and the British Heart Foundation (NH/11/8/29253) for funding.en
dc.description.abstractThis work demonstrates synthetic strategies for the incorporation of an anticancer drug, cisplatin, and a Pt(IV) cisplatin prodrug into two zirconium-based metal-organic-frameworks (MOFs): UiO66 and UiO66-NH2. Cisplatin was chosen due to its reported high potency in killing ca. 95% of different cancers. Two approaches for its incorporation were investigated: conjugation and encapsulation. In the conjugation route, a Pt(IV) cisplatin prodrug was incorporated into UiO66-NH2 utilising its amine group in an amide-coupling reaction. In the second case, cisplatin was encapsulated into the large cavities of both MOFs. The presence of platinum was confirmed by energy-dispersive X-ray spectroscopy and microwave plasma-atomic emission spectroscopy. The cytotoxicity of the formulations was assessed on the A549 lung cancer cell line. The results show that the system in which cisplatin is conjugated to UiO66-NH2 is more efficient in inducing cell death than the materials where cisplatin is encapsulated into the pores of the MOFs. This is consistent with the higher drug loading achieved with the conjugation technique. One disadvantage of cisplatin therapy is that it may lead to thrombosis and, as a consequence, to heart attack and cardiac arrest. To ameliorate this potential side effect, we investigated the incorporation of NO (which has been widely researched for its antithrombotic properties) into the drug-loaded MOFs. All the cisplatin or pro-drug loaded MOFs are able to entrap and then release NO. Furthermore, the amount of NO released from these formulations is much greater than from the pure MOFs. As a result, the drug delivery systems developed in this work have potentially potent double functionality.en
dc.format.extent9en
dc.language.isoeng
dc.relation.ispartofRSC Advancesen
dc.rightsCopyright 2015 the Authors. This article is licensed under a Creative Commons Attribution 3.0 Unported Licence (http://creativecommons.org/licenses/by/3.0/)en
dc.subjectQD Chemistryen
dc.subjectNDASen
dc.subject.lccQDen
dc.titleIncorporation of cisplatin into the metal-organic frameworks UiO66-NH2 and UiO66 – encapsulation vs. conjugation.en
dc.typeJournal articleen
dc.description.versionPublisher PDFen
dc.contributor.institutionUniversity of St Andrews. School of Chemistryen
dc.contributor.institutionUniversity of St Andrews. EaSTCHEMen
dc.identifier.doihttps://doi.org/10.1039/C5RA14011K
dc.description.statusPeer revieweden


The following license files are associated with this item:

This item appears in the following Collection(s)

Show simple item record